INNOTEST® NPTX2

INNOTEST NPTX2 is a solid-phase enzyme immunoassay for the quantitative determination of neuronal pentraxin-2 (NPTX2) in human cerebrospinal fluid (CSF).

Contact sales for information
For research use only
INNOTEST® NPTX2

Product number 80908

96 Tests
NPTX2 CAL-RVC pack

Product number 80909

Please contact your local Fujirebio representative for the availability of this product in your country.

Click here to navigate

  • Contact sales for information
  • Details
  • Conditions of sale
  • Documentation
  • Insights
  • FAQ
  • Product inquiry
  • Related products

  • Details

    This assay should be used in combination with the NPTX2 CAL-RVC pack, article no. 80909 (RUO), of the corresponding lot.
     

    Test principle

    The INNOTEST NPTX2 is a solid-phase enzyme immunoassay in which the neuronal pentraxin-2 protein is captured by a first monoclonal antibody, 33F9 (ADx409; IgG1). CSF samples are added and incubated with a biotinylated antibody, 22H10 (ADx410; IgG2a). This antigen-antibody complex is then detected by a peroxidase-labeled streptavidin. After addition of substrate working solution, samples will develop a color. The color intensity is a measure for the amount of human neuronal pentraxin-2 protein in the sample1,2.

    Test principle INNOTEST NPTX2

    Test principle INNOTEST NPTX2 (SV= streptavidin; HRP= horseradish peroxidase).

     
    Background

    Neuronal pentraxin-2 is a synaptic protein that consistently shows decreased CSF concentrations in Alzheimer’s disease compared to control subjects1,2. Preliminary studies indicate that while CSF NPTX2 correlates poorly with the core CSF biomarkers (β-amyloid and tau) and other synaptic markers, it seems to correlate well with cognitive decline2.

     

    Read about how Fujirebio collaborates closely with the international clinical community and partner organizations to develop the neurodegeneration diagnostic tools of the future >>
     

    References

    1. Jacobs D, et al. A monoclonal antibody based immunoassay for Neuronal Pentraxin2 in CSF. ADPD 2019.
    2. Vanmechelen E, et al. NPTX2 levels in CSF as potential predictor of cognitive dysfunction in the AD continuum. AAIC 2019.

  • Conditions of sale

    To read the end user conditions of sale for this product please visit our Resource center.

  • Insights

  • FAQ

  • Product inquiry

    The provision of your data implies your consent to the processing of your data in our database and, depending on the option you choose, to receiving our monthly newsletter by e-mail.

    For more information on how we process your personal data and regarding the rights you have in this respect, we refer to our privacy policy, which we hold at your disposal HERE.

    If you no longer wish to receive our newsletter, you have the option to unsubscribe via the ‘unsubscribe’ tool at the bottom of the newsletter. If you want to have your data removed from our database, please contact us at: privacy@fujirebio.com.

Veuillez confirmer que vous êtes un professionnel de la santé

Le contenu de ce site web est en partie réservé aux professionnels de santé qui sont directement impliqués dans la fourniture de services de soins de santé aux patients. Si vous êtes un professionnel de santé et que vous disposez de tous les droits d'accès, veuillez confirmer en cliquant sur le bouton 'oui'.